WorksheetsPROVE HF
Total questions: 12
Worksheet time: 6mins
PROVE HF is a double blind randomized trial 48 weeks included 975 hospitalized HFREF patients.
True
False
PROVE HF is a Phase III Trial designed to assess and examine the association between changes in concentration of NT-pro BNP and cardiac remodeling, assessed by echocardiographic parameters of volume ( LV end systolic and diastolic volume indices, LVEF and left atrial volume index) from baseline to 1 year.
True
False
There was a rapid and significant reduction on NT-proBNP observed, with the majority of reduction within the first 2 weeks.
True
False
The following are the primary endpoints included in the PROVE HF Trial except:
Left ventricular ejection fraction (LVEF)
LV end-diastolic volume index (LVEDVi)
LV end-systolic volume index (LVESVi)
Left atrial volume index (LAVi)
new-onset HF and/or ACEi/ARB naïve
Majority of the patients in this trial has previous medical history which includes most common condition like
Hypertension
Stroke
Hypercholesterolemia
COPD
What percentage of patients are taking Beta Blockers?
75%
95%
35%
85%
What percentage of patients experienced reverse cardiac remodeling and experienced an LVEF increase of _>13% at 12 months
25%
29%
28%
What is the target dose of Sac/Val in the PROVE HF Trial?
100mg BID
200mg OD
200mg BID
50mg BID
Patients with implantation of CRT/D within 6months and those with cardiac implantation were also included in the trial
True
False
In the methodology, an echocardiogram was performed at baseline, 6 and 12 months, and interpreted by by a core lab in a clinically and temporally blinded fashion.
True
False
What is the potassium level of patients that were not included in the study?
Potassium >5.2 mEq/L at screening
Potassium <5.2 mEq/L at screening
Potassium >5.0 mEq/L at screening
Reverse cardiac remodeling was comparable among the following subgroup of interest.
New-onset HF/ACEi-ARB naïve
NP < PARADIGM incl criteria
Not reaching target dose
A&B only
A, B & C
